Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma

Journal of the American Academy of Dermatology

Volumn 71, Issue 6, 2014, Pages 1102-1109.e1

  Sanlorenzo, Martina ^a,b   Choudhry, Aditi ^a   Vujic, Igor ^a,c   Posch, Christian ^a,c   Chong, Kim ^a   Johnston, Katia ^a   Meier, Melissa ^a   Osella Abate, Simona ^b   Quaglino, Pietro ^b   Daud, Adil ^a   Algazi, Alain ^a   Rappersberger, Klemens ^c   Ortiz Urda, Susana ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

cutaneous adverse event; histology; inflammation; rash; squamous cell carcinoma therapy

Indexed keywords

B RAF KINASE; COBIMETINIB; DABRAFENIB; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; AZETIDINE DERIVATIVE; BRAF PROTEIN, HUMAN; GDC-0973; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; OXIME; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; SULFONAMIDE;

ACNE; ACTINIC KERATOSIS; ADULT; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG ERUPTION; DRUG SAFETY; ECZEMA; FEMALE; FIBROMA; HAND FOOT SYNDROME; HUMAN; KERATOACANTHOMA; KERATOSIS; MALE; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEVUS; ORAL BLISTER; OUTCOME ASSESSMENT; PANNICULITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY; SKIN CARCINOMA; TREATMENT DURATION; VERRUCA VULGARIS; XEROSIS; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; COMPARATIVE STUDY; FOLLOW UP; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; SKIN NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZETIDINES; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; INDOLES; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; OXIMES; PIPERIDINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SULFONAMIDES; YOUNG ADULT;

EID: 84938207532     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.09.002     Document Type: Article

References (26)

1. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, and J. Larkin Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
2. A. Hauschild, J.J. Grob, L.V. Demidov, T. Jouary, R. Gutzmer, and M. Millward Dabrafenib in BRAF-mutated metastatic melanoma: a multicenter, open-label, phase 3 randomized controlled trial Lancet 380 2012 358 365
3. P. LoRusso, G. Shapiro, S.S. Pandya, E.L. Kwak, C. Jones, and M. Belvin A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors J Clin Oncol 30 15 suppl 2012 abstr2566
4. K.T. Flaherty, C. Robert, P. Hersey, P. Nathan, C. Garbe, and M. Milhem Improved survival with MEK inhibition in BRAF-mutated melanoma N Engl J Med 367 2012 107 114
5. P.A. Ascierto, D. Schadendorf, C. Berking, S.S. Agarwala, C.M. van Herpen, and P. Queirolo MEK162 for patients with advanced melanoma harboring NRAS or Val600 BRAF mutations: a non-randomized, open-label phase 2 study Lancet Oncol 14 2013 249 256
6. J.A. Sosman, K.B. Kim, L. Schuchter, R. Gonzalez, A.C. Pavlick, and J.S. Weber Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 366 2012 707 714
7. R. Nazarian, H. Shi, Q. Wang, X. Kong, R.C. Koya, and H. Lee Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS up-regulation Nature 468 2010 973 977
8. P.I. Poulikakos, Y. Persaud, M. Janakiraman, X. Kong, C. Ng, and G. Moriceau RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) Nature 480 2011 387 390
9. C.M. Johannessen, J.S. Boehm, S.Y. Kim, S.R. Thomas, L. Wardwell, and L.A. Johnson COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Nature 468 2010 968 972
10. K.T. Flaherty, J.R. Infante, A. Daud, R. Gonzalez, R.F. Kefford, and J. Sosman Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N Engl J Med 367 2012 1694 1703
11. US National Institutes of Health. Clinicaltrials.gov. Available from: URL: http://clinicaltrials.gov/. Accessed August 27, 2014.
12. K.T. Flaherty, I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, and J.A. Sosman Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
13. I. Manousaridis, S. Mavridou, S. Goerdt, M. Leverkus, and J. Utikal Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signaling pathway and their management J Eur Acad Dermatol Venereol 27 2013 11 18
14. P.L. Mattei, M.B. Alora-Palli, S. Kraft, D.P. Lawrence, K.T. Flaherty, and A.B. Kimball Cutaneous effects of BRAF inhibitor therapy: a case series Ann Oncol 24 2013 530 537
15. Anforth R, Liu M, Nguyen B, Uribe P, Kefford R, Clements A, et al. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib. Australas J Dermato doi: http://dx.doi.org/10.1111/ajd.12124. Published online December 9, 2013.
16. G. Shapiro, P. LoRusso, E.L. Kwak, J.M. Cleary, L. Musib, and C. Jones Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: a first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors J Clin Oncol 29 suppl 2011 abstr3005
17. C.M. Balch, J.E. Gershenwald, S.-J. Soong, J.F. Thompson, M.B. Atkins, and D.R. Byrd Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 2009 6199 6206
18. National Cancer Institute Common Terminology Criteria for Adverse Events v4.0. NCI, NIH, DHHS; 2009: NIH publication #09-7473.
19. G. Hatzivassiliou, K. Song, I. Yen, B.J. Brandhuber, D.J. Anderson, and R. Alvarado RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth Nature 464 2010 431 435
20. F. Su, A. Viros, C. Milagre, K. Trunzer, G. Bollag, and O. Spleiss RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors N Engl J Med 366 2012 207 215
21. P.A. Oberholzer, D. Kee, P. Dziunycz, A. Sucker, N. Kamsukom, and R. Jones RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors J Clin Oncol 30 2012 316 321
22. R. Dummer, J. Rinderknecht, and S.M. Goldinger Ultraviolet A and photosensitivity during vemurafenib therapy N Engl J Med 366 2012 480 481
23. G.S. Falchook, K.D. Lewis, J.R. Infante, M.S. Gordon, N.J. Vogelzang, and D.J. DeMarini Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial Lancet Oncol 13 2012 782 789
24. A.B. Turke, Y. Song, C. Costa, R. Cook, C.L. Arteaga, and J.M. Asara MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors Cancer Res 72 2012 3228 3237
25. T.M. Smith, K. Gilliland, G.A. Clawson, and D. Thiboutot IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway J Invest Dermatol 128 2008 1286 1293
26. B.C. Melnik FoxO1-the key for the pathogenesis and therapy of acne? J Dtsch Dermatol Ges 8 2010 105 114